Definitive Radiotherapy plus ADT versus ADT for Oligometastatic Prostate Cancer-nonrandomized control study

Status

Recruiting

Phases

Phase 3

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OIN-17013470

Enrollment

Unknown

Registered

2017-11-21

Start date

2017-11-16

Completion date

Unknown

Last updated

2017-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

ADT:ADT

RT+ADT:Radiotherapy + ADT

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Histologic confirmation of malignancy (primary or metastatic tumor); 2. Patient must have 1-3 asypmtomatic metastatic tumor(s) of the bone or soft tissue; 3. Patient may have had prior systemic therapy and/or ADT associated with treatment of their primary prostate cancer; 4. Patient must be = 18 years of age, have the ability to understand, and the willingness to sign, a written informed consent document; 5. Patient must have an Eastern Cooperative Oncology Group performance status = 2.

Exclusion criteria

Exclusion criteria: 1. Castration-resistant prostate cancer (CRPC); 2. Refusal to sign informed consent.

Design outcomes

Primary

Measure	Time frame
metastasis-free survival;	—

Secondary

Measure	Time frame
acute toxicity of RT;late toxicity of RT;local control;PCSS;OS;	—

Countries

China

Contacts

Public ContactGao Xian-shu

Peking University First Hospital

13911208977@139.com+86 010 83575239

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026